JZP-898 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData, Phase I drugs for Metastatic Hepatocellular Carcinoma (HCC) have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how JZP-898’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

JZP-898 overview

JZP-898 is under development for the treatment of relapsed and refractory metastatic solid tumors, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, renal cell carcinoma, hepatocellular carcinoma, gastroesophageal carcinomas, urothelial cell carcinoma, colorectal carcinoma and hematological malignancies. The drug candidate is a fusion polypeptide comprises of IFN alpha polypeptide and the IFN alpha-blocking moiety linked by the protease-cleavable polypeptide linker. It is being developed based on protein engineering technology (PREDATOR). It is administered through intravenous route.

Jazz Pharmaceuticals overview

Jazz Pharmaceuticals is a specialty biopharmaceutical company which identifies, develops, and commercializes medicines with focus on narcolepsy, cancer, pain, and psychiatry. Its marketed products include Xyrem (sodium oxybate) oral solution, Sunosi (solriamfetol), Erwinaze (asparaginase erwinia chrysanthemi), Defitelio (defibrotide sodium), Vyxeos (daunorubicin and cytarabine) liposome for injection, and others. The company also has various pipeline product candidates related to focus areas such as sleep, neurological disorders, hematology, and oncology including hematologic malignancies and solid tumors. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

For a complete picture of JZP-898’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.